BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, has signed an exclusive worldwide license agreement. The agreement, which is part of its ongoing collaboration with the Max Planck Society and the University Medical Center Gottingen (“UMG”), outlines the development and commercialization of VHH antibodies (NanoAbs) targeting Interleukin-17 (“IL-17”) as treatments for all potential indications; the agreement notes that development will start with a focus on psoriasis and psoriatic arthritis. According to the announcement, BiondVax will lead out on the development and commercialization of the NanoAbs, with vivo proof-of-concept expected this year and in vivo anticipated early next year. The agreement adds to the company’s pipeline of biobetter antibodies targeting diseases with large unmet medical needs and represents attractive commercial opportunities. The announcement noted that recent preclinical in vivo data showed that BiondVax’s anti‑SARS‑CoV‑2 NanoAb prevented illness when inhaled prophylactically and led to a shorter, milder illness. “The license of the IL-17 NanoAb from Max Planck is not only an exciting opportunity to develop a unique treatment for psoriasis and other autoimmune diseases but another validation of the productivity of our collaboration with Max Planck and UMG and portends additional significant developments to follow,” said BiondVax Pharmaceuticals CEO Amir Reichman in the press release. “Psoriasis affects millions of people worldwide, and we believe our NanoAbs have the potential to provide a much-needed and vastly improved treatment option.”
To view the full press release, visit https://ibn.fm/PBggh
About BiondVax Pharmaceuticals Ltd.
BiondVax Pharmaceuticals is a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases. Since its inception, the company has executed eight clinical trials including a seven-country, 12,400-participant, phase 3 trial of its vaccine candidate; the company has also built a state-of-the-art manufacturing facility for biopharmaceutical products. With highly experienced pharmaceutical industry leadership, BiondVax is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with an innovative nanosized antibody (“NanoAb”) pipeline. For more information about the company, please visit www.BiondVax.com.
NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.biomedwire.com
BioMedWire is part of the InvestorBrandNetwork